A bevy of diseases common in the third world aren't receiving adequate attention from funders, despite $2.5 billion spent by philanthropic organizations, governments, and pharmaceutical companies in 2007, according to the most comprehensive survey of global health spending conducted to date. That's because approximately 80% of that money went to developing products targeted towards just three diseases -- AIDS, tuberculosis and malaria. "When you look at all the diseases in developing world, there's a lot more than just AIDS, TB and malaria," linkurl:Mary Moran,;http://www.thegeorgeinstitute.org/research/health-policy/team/mary-moran.cfm policy analyst at the George Institute for International Health in Sydney, Australia and first author on the paper announcing the survey results, told __The Scientist__. "It was clear that there are a bunch of diseases that weren't getting enough support." The G-FINDER (Global Funding of Innovation for Neglected Diseases) survey aims to track global R&D investment in "neglected" diseases, defined by their disproportionate prevalence in developing...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?